ORKA-002

Phase 2Small molecule

OOruka Therapeutics, Inc.

ORKA-002 is one of 34 small molecule programs targeting Plaque Psoriasis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Plaque PsoriasisRecruiting

Single DoseActive, not recruiting

Hidradenitis Suppurativa (HS)Recruiting

Plaque PsoriasisPhase 2

Recruiting

Single DosePhase 1

Active, not recruiting

Hidradenitis Suppurativa (HS)Phase 2

Recruiting

Competition

Competitive Landscape

26 competitors in Single Dose

#DrugCompanyPhaseTrials

Namenda

AbbVie

Phase 2

2 2

Lioresal

Novartis

Phase 2

1 3

Daliresp

AstraZeneca

Phase 2

1 4

Cialis

Eli Lilly

Phase 1

3 5

Opdivo

Bristol-Myers Squibb

Phase 1

1 6

Acoziborole

DDrugs for Neglected Diseases

Phase 3

1 7

LP-003

LLongbio Pharma

Phase 2

1 8

ORKA-002

OOruka Therapeutics, Inc.

Phase 2

1 9

Psilocybin

COMPASS Pathways

Phase 1

1 10

Avodart

Akero Therapeutics

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Active, not recruiting

Single Dose

NCT06944379

Q2 2029

Phase 2Recruiting

Plaque Psoriasis

NCT07474792

Q3 2029

Phase 2Recruiting

Hidradenitis Suppurativa (HS)

NCT07783542

Clinical

Trials by Indication[1]

Single Dose1 trial

ORKA-002-211 A Phase I Study to Evaluate ORKA-002 in Healthy Volunteers Following A Single Dose

Active, not recruiting·OOruka Therapeutics, Inc.·Phase 1·NCT06944379·24 enrolled

Hidradenitis Suppurativa (HS)1 trial

A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ORKA-002 in Adult Participants With Moderate-to-Severe Hidradenitis Suppurativa

Recruiting·OOruka Therapeutics, Inc.·Phase 2·NCT07783542·200 enrolled

Plaque Psoriasis1 trial

A Multicenter, Randomized, Double-Blinded, Placebo- Controlled, Dose-Range Finding Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ORKA-002 in Participants With Moderate-to-Severe Plaque Psoriasis

Recruiting·OOruka Therapeutics, Inc.·Phase 2·NCT07474792·160 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for ORKA-002. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ORKA-002 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ORKA-002. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Oruka Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: OOruka Therapeutics, Inc.

ORKA-002

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2029

Q3 2029

Trials by Indication[1]

Single Dose1 trial

Hidradenitis Suppurativa (HS)1 trial

Plaque Psoriasis1 trial

References

Drug Info

Quick Facts

Related News